Shandong Xinhua Pharmaceutical Company Limited Class H (HK:0719) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Shandong Xinhua Pharmaceutical Company Limited has announced the approval of their Naloxone Hydrochloride Injection after passing the generics consistency evaluation by the National Medical Products Administration. This milestone, disclosed on CNINFO and confirmed by the company’s board for its accuracy and completeness, indicates a promising development for the company’s product lineup in the prescription drug category.
For further insights into HK:0719 stock, check out TipRanks’ Stock Analysis page.